Stocks · News reference
BioVie shares are trading lower. The company announced results from Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioVie Says Last On-Treatment Visit Completed In Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID; Expects Topline Results Before End Of September 2026
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out yesterday.
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.